-
公开(公告)号:US20170275626A1
公开(公告)日:2017-09-28
申请号:US15504855
申请日:2015-08-14
发明人: Martin MAIER , Don FOSTER , Stuart MILSTEIN , Satya KUCHIMANCHI , Vasant JADHAV , Kallanthottathil RAJEEV , Muthiah MANOHARAN , Rubina PARMAR
IPC分类号: C12N15/113
CPC分类号: C12N15/113 , C12N15/111 , C12N2310/14 , C12N2310/313 , C12N2310/32 , C12N2310/3231 , C12N2310/332 , C12N2310/335 , C12N2310/344 , C12N2310/346 , C12N2310/351 , C12N2310/533 , C12N2320/51 , C12N2320/52
摘要: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
-
12.
公开(公告)号:US20150119445A1
公开(公告)日:2015-04-30
申请号:US14338161
申请日:2014-07-22
IPC分类号: A61K47/48 , A61K31/713
CPC分类号: A61K47/28 , A61K31/70 , A61K31/7004 , A61K31/7052 , A61K31/7088 , A61K31/713 , A61K47/16 , A61K47/22 , A61K47/543 , A61K47/549 , A61K47/60 , A61K48/00 , C07H21/02 , Y02A50/385 , Y02A50/411 , Y02A50/467 , Y02P20/55
摘要: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)- or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; RN is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
摘要翻译: 本发明提供包含至少一个式(I)亚基的iRNA试剂:其中:A和B各自独立地为O,N(RN)或S; X和Y各自独立地为H,OH,羟基保护基,磷酸基,磷酸二酯基,活化磷酸酯基,活化亚磷酸酯基,亚磷酰胺,固体载体,-P(Z')( Z“)O-核苷,-P(Z')(Z”)O-寡核苷酸,脂质,PEG,类固醇,亲脂性,聚合物,-P(Z')(Z“)O-Linker- OP(Z')(Z“)O-寡核苷酸,核苷酸,寡核苷酸,-P(Z')(Z”) - 式(I),-P(Z')(Z“) - 或 - -R; R是LG,-Linker-LG,或具有如下结构:每次出现LG独立为碳水化合物,例如单糖,二糖,三糖,四糖,寡糖,多糖; 乙烯基,丙基,异丙基,丁基或苄基各自独立地为N, 和Z',Z“,Z”“和Z”“各自独立地为O或S.
-
公开(公告)号:US20240285767A1
公开(公告)日:2024-08-29
申请号:US18589636
申请日:2024-02-28
发明人: Martin MAIER , Muthusamy JAYARAMAN , Akin AKINC , Shigeo MATSUDA , Pachamuthu KANDASAMY , Kallanthottathil G. RAJEEV , Muthiah MANOHARAN , Jayaprakash K. NAIR , Thomas A. BAILLIE
IPC分类号: A61K47/18 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/713 , C07C31/125 , C07C211/09 , C07C211/10 , C07C211/11 , C07C217/08 , C07C229/12 , C07C235/06 , C07C251/38 , C07C323/12 , C07C323/58 , C07C327/22 , C07C327/28 , C07C327/32 , C07D207/32 , C07D233/54 , C07D295/08 , C07D295/12 , C07D295/14 , C07D317/30 , C07F5/02
CPC分类号: A61K47/18 , A61K9/1272 , A61K9/5123 , A61K31/7088 , A61K31/7105 , A61K31/713 , C07C31/125 , C07C211/09 , C07C211/10 , C07C211/11 , C07C217/08 , C07C229/12 , C07C235/06 , C07C251/38 , C07C323/12 , C07C323/58 , C07C327/22 , C07C327/28 , C07C327/32 , C07D207/32 , C07D233/54 , C07D295/08 , C07D295/12 , C07D295/14 , C07D317/30 , C07F5/022
摘要: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
-
公开(公告)号:US20240252653A1
公开(公告)日:2024-08-01
申请号:US18441882
申请日:2024-02-14
发明人: Jayaprakash K. NAIR , Alexander V. KEL'IN , Pachamuthu KANDASAMY , Kallanthottathil G. RAJEEV , Muthiah MANOHARAN
IPC分类号: A61K47/54 , A61K31/7088 , C07C231/14 , C07D207/12 , C07H1/00 , C07H15/26 , C12N15/113
CPC分类号: A61K47/549 , A61K31/7088 , C07C231/14 , C07D207/12 , C07H1/00 , C07H15/26 , C12N15/113 , C12N2310/351 , C12N2320/32
摘要: This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.
-
公开(公告)号:US20240116973A1
公开(公告)日:2024-04-11
申请号:US18272448
申请日:2022-01-14
IPC分类号: C07H19/16 , C12N15/113
CPC分类号: C07H19/16 , C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/333 , C12N2310/344
摘要: One aspect of the present invention relates to double-stranded RNA (dsRNA) molecules comprising a 6-methyladenine nucleobase and capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
-
公开(公告)号:US20210254065A1
公开(公告)日:2021-08-19
申请号:US17243503
申请日:2021-04-28
IPC分类号: C12N15/113 , C12N15/11
摘要: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
-
公开(公告)号:US20210207144A1
公开(公告)日:2021-07-08
申请号:US16956271
申请日:2018-12-21
发明人: Muthiah MANOHARAN , Nate TANEJA , Hartmut Ingo JAHNS , Shigeo MATSUDA , Klaus CHARISSE , Guo HE , Jayaprakash K. NAIR , Christopher BROWN , Mark K. SCHLEGEL , Vasant JADHAV , Martin MAIER
IPC分类号: C12N15/113
摘要: The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specific-site specific/position specific, chirally-modified internucleotide linkages.
-
公开(公告)号:US20200297853A1
公开(公告)日:2020-09-24
申请号:US16861494
申请日:2020-04-29
IPC分类号: A61K47/28 , A61K31/7004 , A61K31/7052 , A61K31/70 , A61K47/60 , A61K47/54 , C07H21/02 , A61K31/7088 , A61K31/713 , A61K47/16 , A61K47/22
摘要: The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):
-
公开(公告)号:US20190184018A1
公开(公告)日:2019-06-20
申请号:US16196628
申请日:2018-11-20
IPC分类号: A61K47/28 , A61K31/70 , A61K47/60 , A61K31/7004 , A61K31/7052 , A61K47/54 , C07H21/02 , A61K31/7088 , A61K47/22 , A61K47/16 , A61K31/713
摘要: The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):
-
公开(公告)号:US20180326070A1
公开(公告)日:2018-11-15
申请号:US15817473
申请日:2017-11-20
IPC分类号: A61K47/28 , C07H21/02 , A61K31/7052 , A61K47/54 , A61K47/22 , A61K47/16 , A61K31/713 , A61K31/7088 , A61K31/7004 , A61K31/70 , A61K47/60 , A61K48/00
CPC分类号: A61K47/28 , A61K31/70 , A61K31/7004 , A61K31/7052 , A61K31/7088 , A61K31/713 , A61K47/16 , A61K47/22 , A61K47/543 , A61K47/549 , A61K47/60 , A61K48/00 , C07H21/02 , Y02A50/385 , Y02A50/411 , Y02A50/467 , Y02P20/55
摘要: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; RN is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
-
-
-
-
-
-
-
-
-